Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Vincent Calvez, Diane Descamps, Jacques Reynes, Mark Wainberg, Brett Begemann, Gregory Weaver


Theradiag has named four members of its newly formed scientific advisory board who will help the company develop a microRNA-based diagnostic for characterizing HIV tropism.

Members of the SAB include Vincent Calvez, a virologist at Pitie Salpetriere Hospital in Paris; Diane Descamps, a researcher at Paris-Diderot University who specializes in HIV resistance; Jacques Reynes, a professor at the University Hospital of Montpellier who studies HIV/AIDS; and Mark Wainberg, director of the McGill AIDS Center at Quebec Jewish General Hospital.

Monsanto has named Brett Begemann as its new president and COO. He most recently served as the company's president and chief commercial officer.

In his expanded role, Begemann will continue to oversee Monsanto's worldwide sales and operations, but will now handle corporate affairs, as well.

Atossa Genetics has appointed Gregory Weaver to its board of directors and named him as a member of its audit committee.

Weaver previously served as CFO of Sirna Therapeutics prior to its acquisition by Merck.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.